Despite the disappointment of some others, I’m relatively satisfied with the update and with progress.
The first thing I’d note is that shareholders have been receiving regular (bi-monthly), detailed updates since Ms Unwin became Chair in April. There was one in May, one in July and now this one. One would be hard-pressed to whinge about that.
The second thing I’d note is that (in my view), demonstrable progress has been made by the company over the past two months. To recap these areas of progress from the newsletter:
Re FPP-mediated drug delivery platform
have established that there is a rapid rate of drug delivery i.e. commencing within minutes with most delivered within 1 hr
have quantified concentration of protein delivered into cell and demonstrated this to be highly superior to TAT CPP-mediated delivery
Re iMYC cancer program
narrowed number of iMYC candidates to 9
provided further evidence of no toxicity from FPP mediated delivery, including in an IV animal model
made modest improvements in PK
demonstrated early indications of efficacy of FPP-OmoMyc construct when delivered via IV in 2 independent animal models of cancer
General
completed a review by international drug discovery and preclinical experts with outputs now being used to refine PYC’s approach to the hit to lead phase
signed 2 new NDAs
Over two months, I think that’s not bad.
PYC Price at posting:
1.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)